Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Director | June 18, 2026 | June 23, 2026 |
| Twist Bioscience CorpTWST · Entity 3619 | Director · Chief Executive Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 24,852 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 24,852 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,248 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Twist Bioscience Corp
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 562,760 |
Ending reported balance
After 2026-10-05 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 1,840 · Balance 565,468 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2026-10-05 · Sale · Disposed 481 · Balance 564,987 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-10-05 · Sale · Disposed 1,017 · Balance 563,970 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 4 · 2026-10-05 · Sale · Disposed 432 · Balance 563,538 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 5 · 2026-10-05 · Sale · Disposed 290 · Balance 563,248 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 6 · 2026-10-05 · Sale · Disposed 297 · Balance 562,951 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 7 · 2026-10-05 · Sale · Disposed 146 · Balance 562,805 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 8 · 2026-10-05 · Sale · Disposed 45 · Balance 562,760 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.33 · Expires 2029-10-23 | Direct | 131,290 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 131,290 F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.85 · Expires 2030-08-31 | Direct | 64,950 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 64,950 F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2025 Filed Jun 23, 2025 21:45 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantRestricted Stock Unit · Derivative | 3,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017989 · form4-06232025_090651.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,576 Underlying: Class A Common Stock · 3,576 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:45 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 12,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017989 · form4-06232025_090651.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,170 | $31.75 | $68,897.50 |
DisclosureSEC source: 0001214659-25-009061 · marketforms-69849.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,460 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,802 | $29.75 | $83,351.09 |
DisclosureSEC source: 0001214659-25-008298 · marketforms-69630.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 649,630 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-007404 · marketforms-69405.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652,432 F1 · kind: Gift to a charitable donor-advised fund Read SEC document |
| May 05, 2025 Filed May 7, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,042 | $37.65 | $189,836.34 |
DisclosureSEC source: 0001214659-25-007101 · marketforms-69370.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655,432 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 492 | $38.73 | $19,056.64 |
DisclosureSEC source: 0001214659-25-005457 · marketforms-69102.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,474 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 20:08 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,726 | $41.68 | $71,932.78 |
DisclosureSEC source: 0001214659-25-004682 · marketforms-68885.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,966 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,402 | $40.91 | $98,273.03 |
DisclosureSEC source: 0001214659-25-004111 · marketforms-68687.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662,692 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,790 | $44.18 | $123,253.83 |
DisclosureSEC source: 0001214659-25-003434 · marketforms-68344.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 665,094 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:15 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,200 | $49.35 | $256,630.40 |
DisclosureSEC source: 0001214659-25-002009 · marketforms-67970.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667,318 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:45 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 546 | $45.59 | $24,892.74 |
DisclosureSEC source: 0001214659-25-000307 · marketforms-67753.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,518 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,654 | $44.90 | $74,269.56 |
DisclosureSEC source: 0001214659-24-020961 · marketforms-67658.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,064 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,216 | $52.70 | $116,792.06 |
DisclosureSEC source: 0001214659-24-020171 · marketforms-67535.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 674,718 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 95,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-020033 · marketforms-67435.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 676,934 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2024 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 22:23 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 7,968 | $48.00 | $382,448.06 |
DisclosureSEC source: 0001214659-24-018892 · marketforms-67324.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,584 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 14,334 | $44.61 | $639,368.07 |
DisclosureSEC source: 0001214659-24-018616 · marketforms-67293.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,552 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| November 06, 2024 Filed Nov 15, 2024 21:05 UTC Amendment | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 14,334 | $44.61 | $639,368.07 |
DisclosureSEC source: 0001214659-24-019252 · marketforms-67370.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,552 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 22:06 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,841 | $41.56 | $201,211.32 |
DisclosureSEC source: 0001214659-24-018500 · marketforms-67278.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 603,886 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 22:06 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 45,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-018500 · marketforms-67278.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 608,727 F1 · shares: Represents performance stock units for which target criteria was determined to have been met on November 4, 2024. 60% of the PSUs remain subject to time-based vesting and will vest on October 1,2025, subject to continued service or acceleration of vesting as provided in the award agreement. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 22:06 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 80,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-018500 · marketforms-67278.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,773 F1 · shares: Represents performance stock units for which target criteria was determined to have been met on November 4, 2024. 60% of the PSUs remain subject to time-based vesting and will vest on October 1,2025, subject to continued service or acceleration of vesting as provided in the award agreement. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 13,605 | $43.21 | $587,885.66 |
DisclosureSEC source: 0001214659-24-017190 · marketforms-67123.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481,918 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,730 | $46.94 | $81,207.93 |
DisclosureSEC source: 0001214659-24-016669 · marketforms-67008.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,523 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:03 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,340 | $39.16 | $91,636.74 |
DisclosureSEC source: 0001214659-24-016289 · marketforms-66949.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497,253 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,139 | $39.93 | $205,179.71 |
DisclosureSEC source: 0001214659-24-014030 · marketforms-66737.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,593 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,114 | $48.00 | $53,474.23 |
DisclosureSEC source: 0001214659-24-012025 · marketforms-66499.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 504,732 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 20:18 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantRestricted Stock Unit · Derivative | 12,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018331 · form4-06272024_080608.xml · derivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,924 Underlying: Class A Common Stock · 12,924 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:42 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 5,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018045 · form4-06242024_090650.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 5,828 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:42 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 5,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018045 · form4-06242024_090650.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,732 | $49.41 | $85,578.12 |
DisclosureSEC source: 0001214659-24-011293 · marketforms-66352.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,846 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,408 | $51.33 | $123,600.23 |
DisclosureSEC source: 0001214659-24-010749 · marketforms-66286.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,578 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,163 | $37.13 | $154,588.84 |
DisclosureSEC source: 0001214659-24-008522 · marketforms-65757.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,986 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,132 | $32.74 | $37,057.15 |
DisclosureSEC source: 0001214659-24-006121 · marketforms-65456.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514,149 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,128 | $33.52 | $37,806.05 |
DisclosureSEC source: 0001214659-24-005016 · marketforms-65310.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 515,281 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,487 | $37.43 | $55,658.41 |
DisclosureSEC source: 0001214659-24-004245 · marketforms-65110.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,409 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 4,722 | $36.59 | $172,777.98 |
DisclosureSEC source: 0001214659-24-002005 · marketforms-64518.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,605 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,181 | $36.86 | $43,531.66 |
DisclosureSEC source: 0001214659-24-000248 · marketforms-63988.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 521,327 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,722 | $38.33 | $66,004.26 |
DisclosureSEC source: 0001214659-23-016697 · marketforms-63904.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,508 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,329 | $24.67 | $57,456.43 |
DisclosureSEC source: 0001214659-23-016151 · marketforms-63719.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,230 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,662 | $24.74 | $65,857.88 |
DisclosureSEC source: 0001214659-23-015499 · marketforms-63581.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,559 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 21:14 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 168,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-014606 · marketforms-63445.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 529,221 F3 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 2, 2023 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 21:14 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 8,223 | $17.31 | $142,340.13 |
DisclosureSEC source: 0001214659-23-014606 · marketforms-63445.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,245 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 21:14 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 44,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-014606 · marketforms-63445.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,468 F1 · shares: Represents performance stock units for which target criteria was determined to have been met on November 2, 2023. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2024, subject to continued service or acceleration of vesting as provided in the award agreement. Read SEC document |
| October 24, 2023 Filed Oct 26, 2023 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 915 | $16.58 | $15,170.70 |
DisclosureSEC source: 0001214659-23-013925 · marketforms-63417.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,857 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,122 | $20.26 | $22,731.72 |
DisclosureSEC source: 0001214659-23-013057 · marketforms-62723.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,772 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 19, 2023 Filed Sep 21, 2023 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,746 | $20.33 | $35,496.18 |
DisclosureSEC source: 0001214659-23-012537 · marketforms-62656.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,894 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 80,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-012165 · marketforms-62553.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,640 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of September 5, 2023 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 20:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,787 | $19.46 | $54,235.02 |
DisclosureSEC source: 0001214659-23-011599 · marketforms-62261.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,785 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 898 | $25.09 | $22,530.82 |
DisclosureSEC source: 0001214659-23-010002 · marketforms-62119.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,572 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 20:17 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantRestricted Stock Unit · Derivative | 5,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043296 · doc4.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,828 Underlying: Class A Common Stock · 5,828 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.